Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.

Other

Alza Corporation

New York University

Technion Research & Development Foundation Ltd

Hadasit Medical Research Services and Development Ltd.

Bio-Lab, Inc.

Sequus Pharmaceuticals, Inc.

Hadassah Medical Organization

Moebius Medical Ltd.

Memorial Sloan Kettering Cancer Center

King's College London

Shaare Zedek Scientific Ltd

Opperbas Holding B.v.

The Bay Zoltan Foundation for Applied Research

Yechezkel Barenholz

Herve Bercovier

Shimon Gatt

Alberto Gabizon

Francis J Martin

Samuel Zalipsky

Martin C Woodle

Hilary Shmeeda

Rivka Cohen

Elijah M Bolotin

Herman Turndorf

Gilbert J Grant

Dvorah Diminsky

Eliezer Kedar

Keren Turjeman

Boris Piskoun

Tova Chajek

Oren Tirosh

Maty Ayal-Hershkovitz

Ron Kohen

Moshe Baru

Dganit Danino

Zvi Eldar

Israel Nur

Shimon Amselem

Richard N Kolesnick

Yaakov Naparstek

Izhak Etsion

Robert M Abra

Avi Schroeder

Arie Dagan

John Maher

Rina Ulmansky

Danilo D Lasic

Janos Szebeni

Abraham Rubinstein

Dmitri Simberg

Gadi Sarfati

Yuval Avnir

Elishalom Yechiel

Yaniv Dolev

Lilianne K Bar

Joshua Katzhendler

Dan Gibson

Jehoshua Katzhendler

Gilad Haran

Erez Koren

Sarit Sivan

Amiram Goldblum

Laszlo Rosivall

Elimelech Rochlin

Yousef Najajreh

Ziv Greenfeld

Stephane Clerc

Ilan Babai

Dorit Nitzan

Grigory Halperin

Aviva Joseph

Ana Catarina Parente Pereira

Tal Peleg-Shulman

Ahuva Cern

Olga Garbuzenko

Kirill Makedonski

Elena Khazanov

Danielle Hirsch-Lerner

Jörg Reimann

Eylon Yavin

Reinhold Schirmbeck

Andreas Ingemann Jensen

Miklos Toth

Alberto A Gabizon

Dorrit Nitzan

Veronica Wasserman

Tareq Jubeh

The present invention provides a pharmaceutical composition for the lubrication of joints, the pharmaceutical composition comprising a non-ionic tonicity agent comprising a polyol, and liposomes comprising at least one membrane comprising at least one phospholipid (PL) selected from a glycerophospholipid (GPL), said GPL having two C-Chydrocarbon chains, being the same or different, and sphingomyelin (SM) having a C-Chydrocarbon chain, the pharmaceutical composition being essentially free of an additional pharmaceutically active agent, wherein the at least one membrane has a phase transition temperature in the range of about 20° C. to about 39° C. and the joint has a joint temperature which is above the phase transition temperature.

Liposomal formulation for joint lubrication

The present disclosure provides a composition of matter comprising liposomes encapsulating in their intraliposomal aqueous compartment at least one active agent, the liposomes having a diameter of at least 200 nm and being embedded in a water insoluble, water absorbed cross-linked polymeric matrix. In one embodiment, the composition of matter is held within an aqueous medium, preferably being in iso-osmotic equilibrium with the intraliposomal aqueous compartments of the liposomes. The present disclosure also provides a method of removal of non-encapsulated active agent from the composition of matter, a method of preparing said composition of matter, a pharmaceutical composition comprising said composition of matter, use of such composition of matter; a method of providing prolonged delivery of a active agent to a subject in need thereof by administering to said subject the composition of matter disclosed herein as well as a package comprising said composition of matter held within said aqueous medium and instructions for use thereof.

Composition of matter comprising liposomes embedded in a polymeric matrix and methods of using same

The present invention provides a pharmaceutical composition for the lubrication of joints, the pharmaceutical composition comprising a non-ionic tonicity agent comprising a polyol, and liposomes comprising at least one membrane comprising at least one phospholipid (PL) selected from a glycerophospholipid (GPL), said GPL having two C12-C18 hydrocarbon chains, being the same or different, and sphingomyelin (SM) having a C12-C18 hydrocarbon chain, the pharmaceutical composition being essentially free of an additional pharmaceutically active agent, wherein the at least one membrane has a phase transition temperature in the range of about 20&#xb0; C. to about 39&#xb0; C. and the joint has a joint temperature which is above the phase transition temperature.

Provided are modified lipid compounds and their use in the formation of lipid assemblies. Also provided are lipid assemblies including (a) an amphoteric lipid including in covalent association with (i) one or more acyl chains; (ii) one or more weak base moiety; (iii) one or more weak acid moiety; the lipid assembly also including (b) one or more additional lipids, at least one of which being a zwitterionic lipid. In some embodiments, the amphoteric lipid is a compound including (a) a tri-functional moiety; (b) two non-phosphate lipid chains associated with two of the functional moieties of said tri-functional moiety; (c) optionally a spacer moiety associated with the third of the functional moieties of said tri-functional moiety; and (d) a polyalkylamine optionally including a short peptide with one to several carboxylic acid residues. Further provided are the uses of the lipid assembly, inter alia, for transfection or cancer treatment.

Lipid assemblies and uses thereof and some pH and electrostatic modulating lipids to be used in said assemblies

The present disclosure provides liposomes comprising a membrane and an intraliposomal aqueous water phase, the membrane comprising at least one liposome forming lipid and the intraliposomal aqueous water phase comprises a salt of a bisphosphonate together with an amphipathic weak base agent (PLAD). An example of a liposome is one comprising co encapsulated in the intraliposomal aqueous water phase N-containing bisphosphonate, such as alendronate, and an anthracycline such as doxorubicin which was shown to increase survival as compared to Doxil or to administrations of liposomal alendronate (PLA) and Doxil (separate liposomes). Such liposomes may carry a targeting moiety exposed at the liposome's outer surface, for example, conjugate of folic acid as a targeting moiety to folate receptor (FT-PLAD). Also provided by the present disclosure is a method of preparing the liposomes and methods of use of the liposomes, at times, in combination with additional active ingredients, such as &#x3b3;&#x3b4; T-cells.

Liposomes co-encapsulating a bisphosphonate and an amphipathic agent

Based on the observation that the application of small amounts of exogenous acid sphingomyelinase to generate endogenous ceramide, or provision of exogenous long-chain natural C16-ceramide resulted in rapid translocation of vacuolar daunorubicin into the nucleus in multi-drug resistant (MDR) cells, the present invention relates to a nano-liposomal preparation that includes C16-ceramide. Exposure of MDR cells to the C16:0 ceramide-based nanoliposomes provide a mechanism to reverse MDR in chemoresistant cells and tumors, by inducing rapid translocation of chemotherapeutic agent from cytoplasmic vesicles to the nucleus.

Ceramide reversal of multi-drug resistance

Provided are liposomes encapsulating mupirocin, with particular benefit for systemic therapeutically effective delivery. Also provided herein are pharmaceutical compositions including the liposomes and methods of using them. The liposomes include a lipid membrane and an intraliposomal compartment, the intraliposomal compartment encapsulating mupirocin, at least one cyclodextrin compound and a pH dependent ionizable anion, e.g. acetate.

Liposomal mupirocin

The present invention provides methods for desensitization for prevention or diminishing hypersensitivity reactions including C activation-related pseudoallergy (CARPA) and other reactions to particulate medicines. The desensitization is performed via pretreatment using a drug-free vehicle or carrier to eliminate or diminish the clinical symptoms of hypersensitivity.

Particulate drug carriers as desensitizing agents

The present invention provides pharmaceutical compositions comprising a glucocorticoid or glucocorticoid derivative stably encapsulated in a liposome. The glucocorticoid or glucocorticoid derivative is selected from an amphipathic weak base glucocorticoid or glucocorticoid derivative having a pKa equal or below 11 and a logD at pH 7 in the range between &#x2212;2.5 and 1.5; or an amphipathic weak acid GC or GC derivative having a pKa above 3.5 and a logD at pH 7 in the range between &#x2212;2.5 and 1.5. The therapeutic effect of the pharmaceutical composition of the invention was exhibited in vivo with appropriate models of multiple sclerosis and cancer.

Liposomal compositions of glucocorticoid and glucocorticoid derivatives

The present invention concerns methods of joint lubrication and/or prevention of cartilage wear making use of liposomes having membranes with at least one phospholipid (PL) of the group consisting of a glycerophospholipid (GPL) having two, being the same or different, C-Chydrocarbon chain and a sphingolipid (SPL) having a C-Chydrocarbon chain, the one or more membranes having a phase transition temperature in which solid ordered (SO) to liquid disordered (LD) phase transition occurs, the phase transition temperature being within a temperature of about 20&#xb0; C. to about 39&#xb0; C. for lubrication of joints.

Methods for joint lubrication and cartilage wear prevention making use of glycerophospholipids

The present invention discloses a dried composition comprising &#x3b2;-casein micelles, assemblies and complexes thereof. The dried composition is stable in the dried state as well as upon re-suspension The dried composition retains the biological activity, drug load capacity, particle size and particle size distribution of the &#x3b2;-casein micelles, assemblies and complexes comprising the active pharmaceutical ingredient, within the dried state and upon resuspension in a buffer or an aqueous pharmaceutical carrier.

Beta-casein assemblies for mucosal delivery of therapeutic bioactive agents

Nanoparticulate assemblies of isolated beta-casein, are useful for encapsulation of bioactive therapeutic substances, particularly therapeutic agents with poor bioavailability. These nano-sized beta-casein assemblies are preferably formed at pH values which are at least one or more pH units below or above the pI of the protein. Pharmaceutical compositions comprising the beta-casein micelles may be used to administer the agents to the GI tract for treatment of local or systemic conditions. These carriers are stable over a wide temperature range (optionally at least from about 1&#xb0; C. to at least about 45&#xb0; C.).

The present invention concerns the use of a sphingoid-polyalkylamine conjugate as a capturing agent of biologically active molecules, such as antigens. In a particular embodiment, the spinogid-polyalkylamines are used for the preparation of pharmaceutical composition for modulating the immune response of a subject. Other aspects of the invention concern methods for modulating the immune response of a subject by the use of the conjugate, complexes comprising, the sphingoid-polyalkylamine conjugate in combination with a biologically active molecule capable of modulating an immune response of a subject, compositions comprising the conjugate as well as kits making use of said conjugate. A preferred conjugate according to the invention is N palmitoyl D-erythro sphingosyl 1 carbamoyl spermine.

Sphingoid polyalkylamine conjugates for vaccination

Growing community of inventors

Jerusalem, Israel

Yechezkel Barenholz